BRIDGEWATER, N.J. — Amneal Pharmaveuticals has announced the launch of its liquid Abilify (aripiprazole) generic. The company is one of the first to launch a generic version of the discontinued Abilify Oral Solution used to treat depression, bipolar disorder and schizophrenia.
“Healthcare providers can now continue prescribing a therapy they are comfortable with and in a form certain patients require,” Amneal EVP sales and marketing Jim Luce said. “It’s a product that would otherwise be unavailable if not for the generic equivalent.”
As of June 2015, aripiprazole oral solution had annual U.S. sales of $62.8 million. Amneal’s liquid aripiprazole is currently shipping in 150-ml bottles direct to the trade and through distributors and wholesalers.